公司资料
Entrada Therapeutics 股价、新闻与催化剂
- 股票代码:
- TRDA
- 交易所:
- NASDAQ
- 行业:
- Biopharma
- 所在地:
- United States
股票表现
7.57 USD (-0.39%)
收盘价
最后更新: 2026年8月21日
258M USD
市值
股价为何变动
As of Aug 21, 2026, TRDA closed down 0.39% at $7.57. No new same-company headline was identified in the current news window.
公司概览
Intracellular Genetic Medicines
Entrada Therapeutics develops Endosomal Escape Vehicle therapeutics intended to deliver oligonucleotides into cells and engage previously inaccessible intracellular targets.
ENTR-601-44
ENTR-601-44 is an exon-skipping candidate for people with Duchenne muscular dystrophy amenable to exon 44 skipping.
ENTR-601-45
ENTR-601-45 applies the same intracellular-delivery platform to patients amenable to exon 45 skipping.
ELEVATE Clinical Program
The ELEVATE studies evaluate multiple ascending doses, safety, target engagement and early functional outcomes to guide further development of Entrada's Duchenne franchise.
未来催化剂
- ELEVATE-45-201 Cohort 1 data around mid-2026.
- ELEVATE-44-201 open-label-period and Cohort 2 data by year-end 2026.
近期新闻
- 01
- 02
- 03
- 04
- 05
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。